

T S Krolevets

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5962094/publications.pdf>

Version: 2024-02-01

11
papers

35
citations

2257263

3
h-index

2053342

5
g-index

15
all docs

15
docs citations

15
times ranked

30
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease. Bulletin of Siberian Medicine, 2022, 20, 112-122.	0.1	0
2	Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Rational Pharmacotherapy in Cardiology, 2022, 17, 880-888.	0.3	3
3	Features of intestinal microbiota disorders in the development of metabolic disorders in non-alcoholic fatty liver disease. Terapevticheskii Arkhiv, 2021, 93, 222-227.	0.2	2
4	Difficulties in differential diagnosis of inflammatory bowel diseases in patient with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Medical Alphabet, 2021, 1, 26-30.	0.0	0
5	Are physicians ready to comply with the guidelines for diagnosis and management of Helicobacter pylori-associated diseases: the survey results 2020â€“2021. AIĖ ¹ manah KliniĖskoj Mediciny, 2021, 49, 455-468.	0.2	3
6	Mo1436 GALLSTONE DISEASE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: THE METABOLIC RISKS. Gastroenterology, 2020, 158, S-876.	0.6	0
7	Neuroendocrine Tumour as a Diagnostic and Prognostic Criterion for Autoimmune Gastritis. Russian Journal of Gastroenterology Hepatology Coloproctology, 2020, 29, 49-59.	0.2	4
8	Decision support system for predicting metabolic risks in patients with comorbid non-alcoholic fatty liver disease and gallstone disease after cholecystectomy. Medical Alphabet, 2020, 1, 11-17.	0.0	3
9	The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease. Russian Journal of Gastroenterology Hepatology Coloproctology, 2020, 30, 42-48.	0.2	0
10	The many faces of the problem of intolerance to gluten.. Klinicheskaja Meditsina, 2018, 96, 123-128.	0.2	3
11	Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Nonalcoholic Fatty Liver Disease. Journal of Pharmacy and Pharmacology, 2016, 4, .	0.1	1